CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase I Study of the Bcl-2/Bcl-XL Inhibitor LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, Philadelphia-Chromosome/BCR::ABL1-Positive Acute Lymphoblastic Leukemia
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT07614022
- Title field or adapter rule
- {'original_value': 'A Phase I Study of the Bcl-2/Bcl-XL Inhibitor LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, Philadelphia-Chromosome/BCR::ABL1-Positive Acute Lymphoblastic Leukemia', 'source_field': 'protocolSection.identificationModule.officialTitle'}
- Ingested At
- 2026-10-31T23:27:29.353227+00:00
- Published At
- 2026-10-29T00:00:00+00:00
- Record Updated At
- 2026-10-29
- Source Retrieved At
- 2026-10-31T22:18:09.361634+00:00
- Timestamp Basis
- ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
- Date limitation
- ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Philadelphia Positive Acute Lymphoblastic Leukemia"]- protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-29", "type": "ACTUAL"}- protocolSection.identificationModule.nctId
"NCT07614022"- protocolSection.identificationModule.officialTitle
"A Phase I Study of the Bcl-2/Bcl-XL Inhibitor LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, Philadelphia-Chromosome/BCR::ABL1-Positive Acute Lymphoblastic Leukemia"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct
null
Study condition terms
Interventions recorded in this study
- {'armGroupLabels': ['Combination of LP-118, ponatinib, dexamethasone, blinatumomab and methotrexate'], 'description': 's LP-118 dosing will be dependent on the dose level to which a participant is assigned:\n\n* 50mg PO\n* 100mg PO\n* 200mg PO\n* 300mg PO', 'name': 'LP-118', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
An intervention appearing in a study record does not establish an effect or an approved use.
Drug names recorded in this source
A recorded drug name is not by itself an indication or a condition-specific relationship.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.